Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Senti Biosciences ( (SNTI) ) has issued an announcement.
Senti Biosciences reported encouraging initial results from a Phase 1 clinical trial of SENTI-202, an innovative CAR-NK cell therapy targeting hematologic malignancies like AML. Two out of three patients achieved complete remission at the initial dose, showing no detectable cancer cells, with the therapy being well-tolerated. The trial continues with dose escalation and further data expected in 2025, offering hope for patients with limited treatment options.
Find detailed analytics on SNTI stock on TipRanks’ Stock Analysis page.
